Oral Tirzepatide at $167-$229: The Price Range Explained

Compounded oral tirzepatide has settled into a $167-$229/month pricing range across the credible providers offering it. Here's what drives that range, how it compares to injectable tirzepatide pricing, and what the format actually delivers.

What Drives the Range

The $167-$229 spread reflects dose tiers within oral tirzepatide programs. Lower doses (equivalent to injectable 2.5-5 mg tirzepatide) command lower pricing at the $167 end. Maintenance doses (equivalent to injectable 10-15 mg) command higher pricing at the $229 end. Different providers position slightly different price points within this range based on their patient acquisition and retention economics.

Why Oral Costs More Per Milligram

Oral tirzepatide requires higher milligram doses to achieve comparable blood levels to injectable, because peptide oral bioavailability is significantly lower than subcutaneous. Compounded oral formulations therefore contain more tirzepatide per dose than injectable equivalents — which is part of what drives per-dose pricing above what raw milligram-cost math would suggest.

Oral vs Injectable Cost Comparison

Compounded injectable tirzepatide pricing typically runs $199-$349/month at credible providers, depending on dose tier and program. Oral compounded pricing at $167-$229 is often cheaper at the low end but comparable at the high end.

The value comparison depends on your priority. Oral saves cost at low doses but not at maintenance. Injectable saves cost at maintenance but not at low doses. Format preference beyond cost — needle tolerance, travel convenience, injection site availability — often ends up as the deciding factor.

Formats Within the Oral Category

Compounded oral tirzepatide ships in one of three formats: orally disintegrating tablets, sublingual troches, or oral drops. Each has slightly different absorption characteristics and slightly different pricing within the same $167-$229 band. Format choice is typically driven by patient preference — no format has established a clear clinical advantage over the others in current data.

Regulatory Stability

Oral tirzepatide's regulatory footing is stronger than injectable compounded tirzepatide because no brand-name oral tirzepatide exists commercially. The "meaningful difference" standard under 503A is met by the alternative route of administration. This regulatory stability is part of why the $167-$229 pricing has held while other segments have moved.

Where to Start